A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA.
Vivian Hernandez-TrujilloChuan ZhouChristopher ScalchunesHans D OchsKathleen E SullivanCharlotte Cunningham-RundlesRamsay L FuleihanFrancisco A BonillaAleksandra PetrovicDavid J RawlingsM Teresa de la MorenaPublished in: Journal of clinical immunology (2023)
Current therapies for XLA patients reduce early mortality, but patients continue to experience complications that impact organ function. With improved life expectancy, more efforts will be required to improve post-diagnosis organ dysfunction and quality of life. Neurologic manifestations are an important co-morbidity associated with mortality and not yet clearly fully understood.